TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Stopped early · Phase 1

Conditions studied: Multiple Myeloma

In brief

The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).

Key facts

Study ID

NCT00243763

Run by

Novartis

People needed

64

Last updated by the study team

2009-11-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of multiple myeloma
• Evidence of relapsed or refractory disease

You may not qualify if…

• Intracranial disease or epidural disease
• Clinically significant cardiac disease
• Diabetes mellitus

Where it is running

• Mayo Clinic - Arizona — Scottsdale, Arizona, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Mayo Clinic - Minnesota — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.